# Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia

Study · id `cardio:ct-nct02899455` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02899455](<https://clinicaltrials.gov/study/NCT02899455>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02899455

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.

## Technical summary

Registry record NCT02899455. Randomized; double masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2016-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 146 participants (enrolled count; ClinicalTrials.gov record NCT02899455, source copy `cardio:ctgov-nct02899455-2016-10-20`, retrieved 2026-10-26)
- Start date: 2014-07 (registry gives no type) (ClinicalTrials.gov record NCT02899455, source copy `cardio:ctgov-nct02899455-2016-10-20`, retrieved 2026-10-26)
- Primary completion: 2016-06 (actual) (ClinicalTrials.gov record NCT02899455, source copy `cardio:ctgov-nct02899455-2016-10-20`, retrieved 2026-10-26)
- Completion: 2016-06 (actual) (ClinicalTrials.gov record NCT02899455, source copy `cardio:ctgov-nct02899455-2016-10-20`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02899455, source copy `cardio:ctgov-nct02899455-2016-10-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02899455-2016-10-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia
- Condition: Hypertension
- Condition: Hyperlipidemia
- Intervention (Drug): HGP0904
- Intervention (Drug): HGP0608
- Intervention (Drug): HGP0816
- Intervention (Drug): HGP0904 Placebo
- Intervention (Drug): HGP0816 Placebo
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia (`cardio:pubmed-29150250`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c7c4120bd6f9df56b64f655d9bf91ba210d061f1a6afd684a062794777b3c0bf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
